Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.

Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P.

JCI Insight. 2019 Jun 25;5. pii: 127552. doi: 10.1172/jci.insight.127552.

2.

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O.

J Clin Oncol. 2019 Aug 1;37(22):1876-1885. doi: 10.1200/JCO.18.02258. Epub 2019 May 1.

PMID:
31042420
3.

Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas.

Fennell L, Dumenil T, Wockner L, Hartel G, Nones K, Bond C, Borowsky J, Liu C, McKeone D, Bowdler L, Montgomery G, Klein K, Hoffmann I, Patch AM, Kazakoff S, Pearson J, Waddell N, Wirapati P, Lochhead P, Imamura Y, Ogino S, Shao R, Tejpar S, Leggett B, Whitehall V.

Cell Mol Gastroenterol Hepatol. 2019;8(2):269-290. doi: 10.1016/j.jcmgh.2019.04.002. Epub 2019 Apr 5.

4.

Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial.

Roelandt P, Demedts I, Willekens H, Bessissow T, Braeye L, Coremans G, Cuyle PJ, Ferrante M, Gevers AM, Hiele M, Osselaer M, Tack J, Tejpar S, Ulenaers M, Van Assche G, Van Cutsem E, Van Gool S, Vannoote J, Vermeire S, Bisschops R.

Endoscopy. 2019 Mar;51(3):237-243. doi: 10.1055/a-0755-7471. Epub 2019 Jan 15.

PMID:
30646403
5.

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, Gebski VJ, Desai J, Segelov E.

Clin Colorectal Cancer. 2018 Dec;17(4):313-319. doi: 10.1016/j.clcc.2018.06.002. Epub 2018 Jun 8.

PMID:
30463680
6.

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.

Mooi JK, Wirapati P, Asher R, Lee CK, Savas P, Price TJ, Townsend A, Hardingham J, Buchanan D, Williams D, Tejpar S, Mariadason JM, Tebbutt NC.

Ann Oncol. 2018 Nov 1;29(11):2240-2246. doi: 10.1093/annonc/mdy410.

PMID:
30247524
7.

Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.

Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, Klingbiel D, Fiocca R, Delorenzi M, Bosman F, Roth AD.

Eur J Cancer. 2018 Aug;99:66-77. doi: 10.1016/j.ejca.2018.05.009. Epub 2018 Jun 14.

PMID:
29909091
8.

Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis.

Lannagan TRM, Lee YK, Wang T, Roper J, Bettington ML, Fennell L, Vrbanac L, Jonavicius L, Somashekar R, Gieniec K, Yang M, Ng JQ, Suzuki N, Ichinose M, Wright JA, Kobayashi H, Putoczki TL, Hayakawa Y, Leedham SJ, Abud HE, Yilmaz ÖH, Marker J, Klebe S, Wirapati P, Mukherjee S, Tejpar S, Leggett BA, Whitehall VLJ, Worthley DL, Woods SL.

Gut. 2019 Apr;68(4):684-692. doi: 10.1136/gutjnl-2017-315920. Epub 2018 Apr 17.

9.

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.

Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M.

Oncotarget. 2018 Feb 13;9(17):13834-13847. doi: 10.18632/oncotarget.24481. eCollection 2018 Mar 2.

10.

Deregulation of ZIC Family Members in Oncogenesis.

Houtmeyers R, Souopgui J, Tejpar S.

Adv Exp Med Biol. 2018;1046:329-338. doi: 10.1007/978-981-10-7311-3_16. Review.

PMID:
29442329
11.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.

PMID:
29370427
12.

A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design.

Morfouace M, Hewitt SM, Salgado R, Hartmann K, Litiere S, Tejpar S, Golfinopoulos V, Lively T, Thurin M, Conley B, Lacombe D.

Semin Cancer Biol. 2018 Oct;52(Pt 2):158-165. doi: 10.1016/j.semcancer.2018.01.003. Epub 2018 Jan 5. Review.

PMID:
29307568
13.

Steps forward for cancer precision medicine.

Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty.

Nat Rev Drug Discov. 2018 Jan;17(1):1-2. doi: 10.1038/nrd.2017.218. Epub 2017 Nov 24.

PMID:
29170471
14.

Societal challenges of precision medicine: Bringing order to chaos.

Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty.

Eur J Cancer. 2017 Oct;84:325-334. doi: 10.1016/j.ejca.2017.07.028. Epub 2017 Sep 4.

PMID:
28865260
15.

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.

Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ.

Eur J Cancer. 2017 Oct;84:69-80. doi: 10.1016/j.ejca.2017.07.016. Epub 2017 Aug 5. Review.

16.

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J.

Ann Oncol. 2017 May 1;28(5):1023-1031. doi: 10.1093/annonc/mdx052.

17.

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20.

PMID:
28404093
18.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J.

Nat Rev Cancer. 2017 Mar 23;17(4):268. doi: 10.1038/nrc.2017.24. No abstract available.

PMID:
28332502
19.

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.

Madi A, Fisher D, Maughan TS, Colley JP, Meade AM, Tejpar S, Van den Bosch B, Maynard J, Humphreys V, Wasan H, Adams RA, Idziaszczyk S, Harris R, Kaplan RS, Cheadle JP.

J Med Genet. 2017 Aug;54(8):567-571. doi: 10.1136/jmedgenet-2016-104317. Epub 2017 Mar 10.

PMID:
28283541
20.

Virtual chromoendoscopy (I-SCAN) detects more polyps in patients with Lynch syndrome: a randomized controlled crossover trial.

Bisschops R, Tejpar S, Willekens H, De Hertogh G, Van Cutsem E.

Endoscopy. 2017 Apr;49(4):342-350. doi: 10.1055/s-0042-121005. Epub 2017 Jan 20.

PMID:
28107763
21.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J.

Nat Rev Cancer. 2017 Feb;17(2):79-92. doi: 10.1038/nrc.2016.126. Epub 2017 Jan 4. Review. Erratum in: Nat Rev Cancer. 2017 Mar 23;17 (4):268.

PMID:
28050011
22.

Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells.

Bosch-Vilaró A, Jacobs B, Pomella V, Abbasi Asbagh L, Kirkland R, Michel J, Singh S, Liu X, Kim P, Weitsman G, Barber PR, Vojnovic B, Ng T, Tejpar S.

Oncotarget. 2017 Jan 17;8(3):4277-4288. doi: 10.18632/oncotarget.13834.

23.

Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.

De Smedt L, Palmans S, Andel D, Govaere O, Boeckx B, Smeets D, Galle E, Wouters J, Barras D, Suffiotti M, Dekervel J, Tousseyn T, De Hertogh G, Prenen H, Tejpar S, Lambrechts D, Sagaert X.

Br J Cancer. 2017 Jan 3;116(1):58-65. doi: 10.1038/bjc.2016.382. Epub 2016 Nov 24.

24.

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V.

JAMA Oncol. 2017 Feb 1;3(2):194-201. doi: 10.1001/jamaoncol.2016.3797. Erratum in: JAMA Oncol. 2017 Dec 1;3(12):1742.

PMID:
27722750
25.

Zic2 mutation causes holoprosencephaly via disruption of NODAL signalling.

Houtmeyers R, Tchouate Gainkam O, Glanville-Jones HA, Van den Bosch B, Chappell A, Barratt KS, Souopgui J, Tejpar S, Arkell RM.

Hum Mol Genet. 2016 Sep 15;25(18):3946-3959. doi: 10.1093/hmg/ddw235. Epub 2016 Jul 27.

PMID:
27466203
26.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

PMID:
27380959
27.

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.

Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M.

Clin Cancer Res. 2017 Jan 1;23(1):104-115. doi: 10.1158/1078-0432.CCR-16-0140. Epub 2016 Jun 27.

28.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J.

BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.

29.

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.

Buhl IK, Gerster S, Delorenzi M, Jensen T, Jensen PB, Bosman F, Tejpar S, Roth A, Brunner N, Hansen A, Knudsen S.

PLoS One. 2016 May 12;11(5):e0155123. doi: 10.1371/journal.pone.0155123. eCollection 2016.

30.

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R.

Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059.

31.

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.

Ciardiello F, Adams R, Tabernero J, Seufferlein T, Taieb J, Moiseyenko V, Ma B, Lopez G, Vansteenkiste JF, Esser R, Tejpar S.

Oncologist. 2016 Mar;21(3):292-300. doi: 10.1634/theoncologist.2015-0279. Epub 2016 Feb 17.

32.

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, Brown S, Barrett JH, Tejpar S, Quirke P, Seymour MT.

JAMA Oncol. 2016 May 1;2(5):633-642. doi: 10.1001/jamaoncol.2015.6065.

PMID:
26867820
33.

Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.

Yan P, Klingbiel D, Saridaki Z, Ceppa P, Curto M, McKee TA, Roth A, Tejpar S, Delorenzi M, Bosman FT, Fiocca R.

Clin Cancer Res. 2016 Jun 15;22(12):3037-47. doi: 10.1158/1078-0432.CCR-15-0939. Epub 2016 Feb 9.

34.

DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, Greil R, Cuyle PJ, Yilmaz M, Faroux R, Matzdorff A, Salazar R, Lepage C, Taieb J, Laurent-Puig P.

JAMA Oncol. 2016 May 1;2(5):655-662. doi: 10.1001/jamaoncol.2015.5392.

PMID:
26794347
35.

Microsatellite Instability and BRAF and KRAS Mutations in Stage III Colon Cancer: Requirements for Accurate Prognosis Assessment.

Klingbiel D, Tejpar S.

JAMA Oncol. 2016 May 1;2(5):653-654. doi: 10.1001/jamaoncol.2015.5226. No abstract available.

PMID:
26768497
36.

Charting the Course for a New Cancer Clinical Research Culture.

Tejpar S, Salgado R; Working Groups ‘Biomarker'' and ‘Clinical Trial Framework'' of the European Alliance for Personalised Medicine (EAPM).

Public Health Genomics. 2015;18(6):381-5. doi: 10.1159/000441558. Epub 2015 Nov 20.

PMID:
26584428
37.

DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.

Nygård SB, Vainer B, Nielsen SL, Bosman F, Tejpar S, Roth A, Delorenzi M, Brünner N, Budinska E.

Clin Cancer Res. 2016 Apr 1;22(7):1621-31. doi: 10.1158/1078-0432.CCR-15-0561. Epub 2015 Nov 5.

38.

Prostatic biopsy-related rectal bleeding refractory to medical and endoscopic therapy definitively managed by catheter-directed embolotherapy: a case report.

De Beule T, Carels K, Tejpar S, Van Cleynenbreugel B, Oyen R, Maleux G.

J Med Case Rep. 2015 Oct 29;9:242. doi: 10.1186/s13256-015-0727-0.

39.

Expression of FOXP1 and Colorectal Cancer Prognosis.

De Smedt L, Palmans S, Govaere O, Moisse M, Boeckx B, De Hertogh G, Prenen H, Van Cutsem E, Tejpar S, Tousseyn T, Sagaert X.

Lab Med. 2015 Fall;46(4):299-311. doi: 10.1309/LM7IHV2NJI1PHMXC.

PMID:
26489674
40.

The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.

41.

Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.

Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Teh C, Tejpar S, Van Cutsem E, Vauthey JN, Påhlman L; of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group.

Cancer Treat Rev. 2015 Nov;41(9):729-41. doi: 10.1016/j.ctrv.2015.06.006. Epub 2015 Jun 30. Review.

42.

Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.

D'Haene N, Le Mercier M, De Nève N, Blanchard O, Delaunoy M, El Housni H, Dessars B, Heimann P, Remmelink M, Demetter P, Tejpar S, Salmon I.

PLoS One. 2015 Sep 14;10(9):e0138245. doi: 10.1371/journal.pone.0138245. eCollection 2015.

43.

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?

Saridaki Z, Saegart X, De Vriendt V, Hatzidaki D, Palmans S, De Smedt L, De Hertogh G, Tejpar S.

Br J Cancer. 2015 Sep 15;113(6):914-20. doi: 10.1038/bjc.2015.307. Epub 2015 Sep 1.

44.

Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURIN Is Not Prognostic to Colon Cancer.

Declercq J, Jacobs B, Biesmans B, Roth A, Klingbiel D, Tejpar S, Creemers JW.

Biomed Res Int. 2015;2015:321276. doi: 10.1155/2015/321276. Epub 2015 Jun 7.

45.

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis.

De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, Prenen H, Tejpar S, Spaepen M, Matthijs G, Decaestecker C, Moles Lopez X, Demetter P, Salmon I, Sagaert X.

Br J Cancer. 2015 Jul 28;113(3):500-9. doi: 10.1038/bjc.2015.213. Epub 2015 Jun 11.

46.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F.

Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19.

47.

Integrating biomarkers in colorectal cancer trials in the West and China.

Tejpar S, Shen L, Wang X, Schilsky RL.

Nat Rev Clin Oncol. 2015 Sep;12(9):553-60. doi: 10.1038/nrclinonc.2015.88. Epub 2015 May 12. Review.

PMID:
25963094
48.

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.

Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S.

Eur J Cancer. 2015 Jul;51(10):1243-52. doi: 10.1016/j.ejca.2015.04.007. Epub 2015 Apr 30.

PMID:
25937522
49.

Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.

Jensen NF, Stenvang J, Beck MK, Hanáková B, Belling KC, Do KN, Viuff B, Nygård SB, Gupta R, Rasmussen MH, Tarpgaard LS, Hansen TP, Budinská E, Pfeiffer P, Bosman F, Tejpar S, Roth A, Delorenzi M, Andersen CL, Rømer MU, Brünner N, Moreira JM.

Mol Oncol. 2015 Jun;9(6):1169-85. doi: 10.1016/j.molonc.2015.02.008. Epub 2015 Feb 24.

50.

Response.

Delorenzi M, Tejpar S, Roth AD, Bosman FT; all authors.

J Natl Cancer Inst. 2015 Mar 10;107(5). pii: djv056. doi: 10.1093/jnci/djv056. No abstract available.

PMID:
25758032

Supplemental Content

Loading ...
Support Center